Trifluoperazine (hydrochloride) – 10 g

Brand:
Cayman
CAS:
440-17-5
Storage:
-20
UN-No:
Non-Hazardous - /

Trifluoperazine (TFP) is a phenothiazine compound with anti-adrenergic and anti-dopaminergic actions typical of antipsychotic agents. It antagonizes adrenergic receptors, with selectivity for α1 over the α2 subtypes (Kis = 24, 653, 163, and 391 nM for α1A, α2A, α2B, and α2C, respectively).{24253} TFP binds with much higher affinity to the dopamine D2-like receptor (Kd = 0.96 nM) compared to the dopamine D4-like and the serotonin 5-HT2A receptors (Kds = 44 and 135 nM, respectively).{24252} Furthermore, TFP antagonizes calmodulin (CaM) and alters the calcium-binding properties of calsequestrin (CSQ).{23719,24254} TFP has been shown to activate type-2 ryanodine receptors independently of its CaM and CSQ activity.{24254}  

 

SKU: - Category:

Description

A phenothiazine compound with anti-adrenergic (Kis = 24, 653, 163, and 391 nM for α1A, α2A, α2B, and α2C receptors, respectively) and antidopaminergic (Kd = 0.96 nM for the dopamine D2-like receptor) actions typical of antipsychotic agents; also antagonizes calmodulin and alters the calcium-binding properties of calsequestrin


Formal name: 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine, dihydrochloride

Synonyms:  SKF 5019|TFP

Molecular weight: 480.4

CAS: 440-17-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Ion Channel Modulation|Activators||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cell Biology|Cell Signaling|Calcium Mobilization||Research Area|Neuroscience|Behavioral Neuroscience|Schizophrenia & Psychosis